Prognostic impact of somatic mutations among patients with pleural and peritoneal mesothelioma.
Prognostic impact of somatic mutations among patients with pleural and peritoneal mesothelioma. NPJ Precis Oncol. 2026 Jul 09; 10(1).
PMID: 42426379
The Society of Thoracic Surgeons 2026 Expert Consensus on the Multimodal Treatment of Pleural Mesothelioma.
The Society of Thoracic Surgeons 2026 Expert Consensus on the Multimodal Treatment of Pleural Mesothelioma. Ann Thorac Surg. 2026 07; 122(1):3-21.
PMID: 42019659
The International Association for the Study of Lung Cancer Pleural Mesothelioma Staging Project: Impact of Common Molecular Alterations and Programmed Death-Ligand 1 Expression on Overall Survival in a Select Cohort From the International Association for the Study of Lung Cancer Ninth Edition Staging Database.
The International Association for the Study of Lung Cancer Pleural Mesothelioma Staging Project: Impact of Common Molecular Alterations and Programmed Death-Ligand 1 Expression on Overall Survival in a Select Cohort From the International Association for the Study of Lung Cancer Ninth Edition Staging Database. J Thorac Oncol. 2026 Jul; 21(7):103681.
PMID: 41833817
Germline genetic testing and privacy concerns in patients with mesothelioma.
Germline genetic testing and privacy concerns in patients with mesothelioma. Genet Med. 2026 05; 28(5):102550.
PMID: 41795597
YAP/TEAD inhibitor VT3989 in solid tumors: a phase 1/2 trial.
YAP/TEAD inhibitor VT3989 in solid tumors: a phase 1/2 trial. Nat Med. 2025 Dec; 31(12):4281-4290.
PMID: 41111090
Mesothelioma of the Tunica Vaginalis Testis.
Mesothelioma of the Tunica Vaginalis Testis. Clin Genitourin Cancer. 2025 Dec; 23(6):102409.
PMID: 40914026
Consensus guideline for the management of peritoneal mesothelioma.
Consensus guideline for the management of peritoneal mesothelioma. Cancer. 2025 Jul 01; 131(13):e35868.
PMID: 40558081
Immune Composition and Immunotherapy Outcomes of Mesothelioma With BAP1, CDKN2A, MTAP, and NF2 Alterations.
Immune Composition and Immunotherapy Outcomes of Mesothelioma With BAP1, CDKN2A, MTAP, and NF2 Alterations. J Thorac Oncol. 2025 11; 20(11):1615-1625.
PMID: 40578509
Consensus Guideline for the Management of Peritoneal Mesothelioma.
Consensus Guideline for the Management of Peritoneal Mesothelioma. Ann Surg Oncol. 2026 Jun; 33(6):5125-5141.
PMID: 40560500
Exceptional responders to immunotherapy in pancreatic cancer: A multi-institutional case series of a rare occurrence.
Exceptional responders to immunotherapy in pancreatic cancer: A multi-institutional case series of a rare occurrence. Oncotarget. 2025 06 10; 16:427-442.
PMID: 40492845